Clinical Trial

An Exploratory Clinical Study of SCAR02 Targeting BCMA and CD19 for the Treatment of Refractory Autoimmune Diseases

Study acronym: SCAR02
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 24, 2025 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is an open label, single-site, dose-escalation study in up to 18 participants with refractory autoimmune diseases. This study aims to evaluate the safety and efficacy of the treatment with Anti-BCMA and CD19 CART
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-07-14.
Trial Details
NCT Number NCT06503224
Lead Sponsor The First Affiliated Hospital of University of Science and Technology of China
Conditions Autoimmune Diseases
Enrollment 18 participants
Start Date 2024-04-09
Primary Completion 2026-04-30 (estimated)
Study Completion 2028-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-24